Enanta Pharmaceuticals Inc (ENTA)

[Jake2234]

Happy to post the data:

https://ir.pardesbio.com/news-releases/news-release-details/pardes-biosciences-announces-top-line-results-phase-2-trial

To simplify for you, look at the “p values”. For the drug to work (in this real world setting that some folks here seem to forget is the only important thing), the p value needs to be below 0.05.

For rsv, please remember that they ran a challenge study which showed stat sig antiviral effects. Want to stress that this is a highly controlled setting. Dosing began right after innoculation, and it was the same for every participant. The lesson with the failure of RSVP contrasted against the challenge study is that it is nearly impossible to catch these people in time, and do so with uniformity, to achieve p less than 0.05.
For babies, elderly, and immunosuppressed, yes, could give better p value. But Enrollment is clearly very slow. Don’t forget, Pfizer acquired Reviral and all of their small molecule RSV assets. It’s another big risk for their RSV program.